Last reviewed · How we verify

Calciferol

Department of Medical Services Ministry of Public Health of Thailand · Phase 1 active Small molecule

Calciferol is a Small molecule drug developed by Department of Medical Services Ministry of Public Health of Thailand. It is currently in Phase 1 development for Familial x-linked hypophosphatemic vitamin D refractory rickets, Glucocorticoid Induced Osteoporosis, Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis. Also known as: vitimin d2, Vitamin D, Vitamin D3.

Likelihood of approval
9.6% vs 9.6% industry baseline
If approved by FDA: likely 2033–2036
Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 1 → approval rate +9.6pp
    Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2033–2036
EMA EU 2034–2037 +0.7 yr
MHRA GB 2034–2037 +0.7 yr
Health Canada CA 2034–2038 +0.9 yr
TGA AU 2034–2038 +1.2 yr
PMDA JP 2034–2038 +1.5 yr
NMPA CN 2035–2039 +2.3 yr
MFDS KR 2034–2038 +1.4 yr
CDSCO IN 2034–2039 +1.8 yr
ANVISA BR 2035–2039 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameCalciferol
Also known asvitimin d2, Vitamin D, Vitamin D3
SponsorDepartment of Medical Services Ministry of Public Health of Thailand
TargetVitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D3 receptor
ModalitySmall molecule
Therapeutic areaNephrology
PhasePhase 1

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Calciferol

What is Calciferol?

Calciferol is a Small molecule drug developed by Department of Medical Services Ministry of Public Health of Thailand, indicated for Familial x-linked hypophosphatemic vitamin D refractory rickets, Glucocorticoid Induced Osteoporosis, Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis.

What is Calciferol used for?

Calciferol is indicated for Familial x-linked hypophosphatemic vitamin D refractory rickets, Glucocorticoid Induced Osteoporosis, Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis, Hypocalcemia, Hypogonadal Osteoporosis in Males.

Who makes Calciferol?

Calciferol is developed by Department of Medical Services Ministry of Public Health of Thailand (see full Department of Medical Services Ministry of Public Health of Thailand pipeline at /company/department-of-medical-services-ministry-of-public-health-of-thailand).

Is Calciferol also known as anything else?

Calciferol is also known as vitimin d2, Vitamin D, Vitamin D3.

What development phase is Calciferol in?

Calciferol is in Phase 1.

What does Calciferol target?

Calciferol targets Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D3 receptor.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing